Overview

Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male Subjects

Status:
Completed

Trial end date:
2010-02-25

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to compare the steady-state pharmacokinetic profile of paroxetine CR (controlled-release) at the dosage of 25mg/day using the proposed final market tablet of CR 25mg in Japan with that of standard paroxetine IR(immediate-release ) at the dosage of 20mg/day using the currently marketed tablet of IR 20mg in Japan.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Paroxetine